NPPB and hydrops fetalis: Findings from these two trials are corroborated by an analysis of the PARADIGM-HF trial demonstrating that reduction of NT-proBNP levels to ≤ 1,000 pg/ml was associated with reduced risk of cardiovascular mortality or HF hospitalization irrespective of treatment group [33].